sign in sign up
<<
Home , Baritosis

Index

A — in microscopic polyangiitis, 143 — , 99 ABPA, 69, 71 — p-ANCA, 143, 144, 147, 148 — BOOP, 57, 59 Acinus-terminal respiratory unit, 8 —— in Wegener granulomatosis, 135, 136, 139 — cell profiles, 16 Acute hypersensitive , ground- Anti Scl-70 antibodies, 113, 115 — CEP, 72 glass attenuation, 22 Anti-GBM disease see Goodpasture disease — Crohn disease, 196 Acute interstitial (AIP), 4, 37, Anti-GMB antibodies, 135 — CSS, 147, 150 61–63 Anti–GM-CSF autoantibodies, 167 — DIP, 47 — clinical conditions associated, 62 Antimoniosis, 101 — drug-induced lung diseases, 75, 77 — diagnosis procedure, 61, 63 Anti-neutrophil cytoplasmic autoantibodies — hypersensitivity pneumonitis, 95 — histopathological findings, 61, 62 see ANCAs — idiopathic , 43 — lung lavage cell profiles, 16 Anti-nuclear antibodies (ANA), in SLE, 119, — in IIP diagnosis, 38–39 — pathogenesis, 61 120, 121 — IPF, 43 — symptoms, 61 Antiphospholipid syndrome, 123 — IPH, 159, 162 — therapy, 63 ARDS see acute respiratory distress syndrome — Langerhans cell histiocytosis, 177 Acute lupus pneumonitis, 119 Asbestosis, 97, 99 — LIP, 65 Acute respiratory distress syndrome (ARDS), — malignant mesothelioma with, 201 — NSIP, 52 in pancreatitis, 193, 194 , heroin-related, 85 — PAM, 163 Acute silicoproteinosis, 97 — PAP, 167, 168, 169 AIP see acute interstitial pneumonia B — RB-ILD, 47, 49 , interstitial lung disease BAL see bronchoalveolar lavage — rheumatoid arthritis, 110 and, 12, 15 Ball, R., 107 — Sjögren syndrome, 129 Allergic bronchopulmonary aspergillosis BALT see associated lymphoid tissue — SLE, 123 (ABPA), 69, 71 Baritosis, 101 — systemic sclerosis, 113 Alpha heavy-chain disease, 187 Behçet disease (BD), 155, 156–157 — Wegener granulomatosis, 139 Alpha-1 antitrypsin deficiency, 190 — pathology, 155, 157 Bronchocentric granulomatosis, 69 Alveolar cell carcinoma, 199 — symptoms, 155, 156 Bronchoscopy Alveolar cell hyperplasia, 199 — treatment, 155 — IPH, 159, 162 Alveolar hemorrhage, cocaine-induced, 88 Benign , 101 — , 35 Alveolar lymphocytosis, in Crohn disease, 196 , 101 — Wegener granulomatosis, 137, 138, 139 Alveolar macrophages, 10 Bilateral hilar adenopathy (BHL), in Bronchus associated lymphoid tissue (BALT), Alveolar proteinosis, lung lavage cell profiles, sarcoidosis, 32 proliferations, 65 16 Bioactivation, of xenobiotics, 75, 76 Alveolar walls, 8 Biotransformation, 75, 76 C Alveolocapillary membrane, 8 Biperidine, interstitial reactions, 78 Calcinosis, in multiple myeloma, 186 Amiodarone BOOP see obliterans organizing Cancer, in interstitial lung disease, 199–202 — cytological appearance of exposure, 77 pneumonia Cannabis, 86 — lung toxicity, 76–77 Breast cancer, 199 Caplan syndrome, large nodules in, 21 Ammonium, effects, 104 Bronchiolitis obliterans interstitial pneumonia Cardiac sarcoidosis, 25, 29, 36 Amyloidosis, 181–185 (BIP), 3 Carrington, C. B., 65 — diagnosis, 182–183, 185 Bronchiolitis obliterans organizing pneumonia Cavitary lung diseases, causes, 173 — diffuse alveolar, 182 (BOOP), 4, 37, 57–59 Celiac disease, 159 — hilar adenopathy in, 182, 184 — clinical conditions associated, 58 Central peribronchovascular thickening, 20 — mediastinal, 182 — as cliniopathologic entity, 57 CEP see chronic — parenchymal nodules, 181–182 — cocaine-induced, 88 Charcot, J. M., 1, 3 — pleural involvement, 182, 184 — diagnosis, 57 , 103–105 — primary, 181 — histopathological finding, 59 — causative agents, 104 — therapy, 183 — Idiopathic Chest radiographs see radiographs — tracheobronchial, 181, 183 — lung lavage cell profiles, 16 Chest roentgenogram see radiographs ANCA-positive vasculitis, cocaine abuse and, — pathogenesis, 57 Chronic airway inflammation, in IBD, 194, 195, 88 — toxic fume-induced, 103 196 ANCAs — treatment, 59 Chronic eosinophilic pneumonia (CEP), 69, — c-ANCAs, 136, 139 Bronchoalveolar lavage (BAL), 15–16 72 — in CSS, 147, 148 — AIP, 61 Chronic phthisis, fibrosis development in, 2 203 204 Index

Chronic pneumonitis, 1 DM see dermatomyositis Heerfordt syndrome, 25 — caused by syphilis, 2 Drug addict’s lung, 85–88 Heliotrope rash, 126 Churg-Strauss syndrome (CSS), 147–150 Drug-induced lung diseases, 75–78 Hemosiderin, 159 — classification, 148 — classification by clinical features, 76 Hepato-pulmonary syndrome, 189 — clinical features, 147, 148 — diagnosis, 75 Heroin, 85, 86 — consolidation in, 22 — history, 75 — acute complications, 85 — diagnosis, 147 — prevalence, 75 — chronic complications, 85, 86, 87 — incidence, 147 — rechallenge test, 75 Heroin-abuser lung, 85 — phases, 147 Drug-induced pneumonitis, lung lavage cell High-intensity lymphocytic alveolitis, in — prognosis, 147 profiles, 16 hypersensitivity pneumonitis, 91, 95 — therapy, 147 Dry eye, 129, 130 High-resolution computed tomography see Cigarette smoking see smoking Dry mouth, 129, 131 HRCT Cirrhosis, hyperventilation and, 189 Dyspnea,7,10 Hilar adenopathy Cirrhosis of the lung, 1 — in amyloidosis, 182, 184 Clubbing, 11 E — in MGUS, 187 — interstitial pneumonitis/fibrosis and, 1 Ellman, P., 107 Hinson, K., 3 — in IPF, 41, 42 Emphysema, 190 Histoplasmosis, 69 Coal miner’s pneumoconiosis, 97, 99 Eosinophilic interstitial lung disease, 69–73 HMB45, 171, 172 Cocaine, 86, 88 — classification, 70 Hoarseness, rheumatoid arthritis-related, 107, Coccidioidomycosis, 69 — clinical conditions associated, 73 109 Connective tissue disease, lung lavage cell Eosinophilic pneumonia, lung lavage cell Honeycombing, 22, 23 profiles, 16 profiles, 16 — in IPF, 22 Consolidation, 22, 23 Erythema nodosum, 11 HP see hypersensitivity pneumonitis — in Churg-Strauss syndrome, 22 Esophageal scleropathy, pulmonary HRCT, 12, 19–23 Corrigan, Dominic, 1, 3 complications, 193 — AIP, 57 Crack, 88 Esophagus disease, in systemic sclerosis, 113, — amyloidosis, 182, 184 CREST syndrome, 113 116, 193, 194 — BOOP, 57, 58, 59 — PBC and, 191 Extrinsic allergic alveolitis see hypersensitivity — CSS, 147, 149 Crohn disease, 196, 197 pneumonitis — DIP, 47, 49 Cryptococcosis, 69 Eyes, in sarcoidosis, 25, 28, 36 — drug-induced lung diseases, 75, 78 Cryptogenic fibrosing alveolitis, 3 — finding in common interstitial lung — see also idiopathic pulmonary fibrosis F diseases, 23 Cryptogenic organizing pneumonia (COP) see Farmer’s lung, 94 — hard-metal pneumoconiosis, 100 bronchiolitis obliterans organizing Fibroblasts, proliferation in IPF, 41 — hypersensitivity pneumonitis, 93, 94 pneumonia Flint, Austin, 1, 3 — IPF, 43, 44 CSS see Churg-Strauss syndrome Flow-volume loops, 14 — IPH, 159, 160, 161 Cutaneous sarcoidosis, 26–27 Flufenazine, interstitial reactions, 78 — LAM, 171, 172, 173 Cystic lung diseases, causes, 173 Fox,Wilson,1,2,3 — Langerhans cell histiocytosis, 175, 176 Cysts, lung see lung cysts Frank, S., 107 — LIP, 65, 66 Cytokines, release, in IPF, 41 — lung cancer, 200 G — lymphangitic carcinomatosis, 202 D Gallium-67 citrate, 19 — migratory radiation pneumonitis, 83 DAD see Gallium-67 scanning, 19, 20 — NSIP, 51–52, 53, 54 DAH see diffuse alveolar hemorrhage Gamma heavy-chain disease, 187 — PAM, 163, 164 Dermatomyositis (DM), 125–127 Gastric cancers, 201 — PAP, 167, 168 — interstitial lung disease in, 125 Gastroesophageal reflux disease, 193, 194 — PM/DM, 125, 127 — pulmonary manifestations, 125, 126 Gastrointestinal system, lungs and, — pulmonary involvement in rheumatoid — treatment, 125 193–197 arthritis, 107, 109, 110 Desquamative interstitial pneumonia (DIP), 3, Genital ulcers, in Behçet disease, 155 — PVOD, 155, 158 4, 37, 47–49 Giant cell interstitial pneumonia (GIP), 3 — sarcoidosis, 33 — clinical features, 47 — in hard-metal pneumoconiosis, 100 —— vs IPF, 14 — diagnostic procedure, 47 GM-CSF, 167 — Sjögren syndrome, 129, 132 — histopathological findings, 47, 48 Goodpasture disease, 151–153 — SLE, 119, 121, 122 — lung lavage cell profiles, 16 — clinical features, 151, 152 — systemic sclerosis, 113, 117 — RB-ILD vs, 49 — diagnosis, 151 — toxic inhalation injuries, 104, 105 Diamond polisher lung, 100 — histopathology, 151, 152 — Wegener granulomatosis, 137, 138 Diffuse alveolar damage (DAD), 61 — symptoms, 151 Hypercalcemia, in sarcoidosis, 25 — clinical conditions associated, 62 — treatment, 151, 153 Hypercalcuria, in sarcoidosis, 25 Diffuse alveolar hemorrhage (DAH), 39 Ground-glass attenuation, 22, 23 Hypereosinophilic pneumonia, 69 — causes, 160 — in acute hypersensitive pneumonitis, 22 Hypersensitivity pneumonitis (HP), 91–95 — lung lavage cell profiles, 16 — acute, 91, 92 — in microscopic polyangiitis, 143, 145 H — causes, 92 — in SLE, 119, 121 Hamman, Louis, 1, 3, 61 — chronic, 91, 94 — in Wegener granulomatosis, 139 Hamman-Rich syndrome, 3, 4 — clinical diagnosis, 91 Diffuse parenchymal lung disease (DPLD), — see also acute interstitial pneumonia — lung lavage cell profiles, 16 definition, 7 Hard-metal pneumoconiosis, 100 — pathogenetic mechanisms, 91 DIP see desquamative interstitial pneumonia Hashish, 86 — pathologic mechanisms, 91 Dirofilaria, 69, 70 Heavy-chain diseases, 187 — presentation, 91 Index 205

— prevention and management, 95 Interstitial pneumonia, 3 Lung lavage cell profiles, in common — subacute, 91, 93 Interstitial pneumonitis, classification, 3 interstitial lung diseases, 16 Hyperventilation, cirrhosis and, 189 Interstitium, 8 Lung parenchyma Intralobular thickening, in idiopathic — cell types, 10 I pulmonary fibrosis, 21 — structure, 8–10 IBD see inflammatory bowel disease IPF see idiopathic pulmonary fibrosis —— see also parenchymal shadows Idiopathic hypereosinophilic pneumonia, 73 Iridocyclitis, 28 Lungs Idiopathic interstitial (IIPs), — gastrointestinal system and, 193–197 37–39 J — in sarcoidosis, 25, 35, 36 — classification, 37 Jejunal villous atrophy, 159 Lupus pernio, 25, 27 — clinico-radiologic-pathologic diagnosis, 37, Jo-1 antibody, 125, 127 Lymph nodes, in sarcoidosis, 25, 30 38 Joints, in sarcoidosis, 25, 31 Lymphangioleiomyomatosis (LAM), 171–174 — diagnosis, 37–39 — cause, 171 — histological pattern, 37 K — clinical course, 171, 174 — histopathological findings, 38–39 Kanada, D., 182 — diagnostic procedure, 171 — history, 37 Kaposi sarcoma, thallium-201 imaging, 19 — lung cysts, 22, 23 — physical finding, 37 Kidney biopsy, Goodpasture disease, 151, 152 — symptoms, 171 — radiological imaging of lungs, 37–38 — treatment, 171 Idiopathic pulmonary fibrosis (IPF), 3, 37, L — tuberous sclerosis and, 171 41–45 Laboratory tests, 12, 15 Lymphangitic carcinomatosis, 201, 202 — chest x-ray, 43 Lachrymal gland, in sarcoidosis, 25, 31 — interlobular thickening, 21 — clinical presentation, 41 LAM see lymphangioleiomyomatosis Lymphocytic alveolitis, in sarcoidosis, 35 — diagnosis, 41 Lambda sign, 19, 20 Lymphoid interstitial pneumonia (LIP), 3, 4, —— approach, 43 Langerhans cell histiocytosis (LCH), 38 37, 65–66 —— criteria, 42 — diagnostic procedures, 175 — cause, 65 — etiological agents, 41 — etiology, 175 — clinical conditions associated, 66 — gastroesophageal reflux and, 193 — histopathological findings, 177–178 — diagnostic procedure, 65 — honeycombing, 22 — lung cysts, 22, 175, 176, 178 — histopathological findings, 65, 66 — intralobular thickening, 21 — lung lavage cell profiles, 16 — in Sjögren syndrome, 129, 132 — lung lavage cell profiles, 16 — symptoms, 175 — symptoms, 65 — prevalence, 41 — therapy, 178 — treatment, 65 — sarcoidosis vs, 14 Langerhans cells, effect of cigarette smoke, 175 — therapy, 44–45 Latex agglutination test, 167 M — usual interstitial pneumonitis and, 41, 43, LCH see Langerhans cell histiocytosis Magnetic resonance imaging (MRI), 19 44 Leukocytoplastic vasculitis purpura, 109 Malignant mesothelioma, with asbestosis, Idiopathic pulmonary hemosiderosis (IPH), Leung, A., 19 201 159–162 Liebow,Averill,3,4,65 Mediastinal adenopathy — diagnosis, 159 Lines, as HRCT finding, 23 — in amyloidosis, 182 — etiology, 159 LIP see lymphoid interstitial pneumonia — in MGUS, 187 — symptoms, 159 Liver, in sarcoidosis, 25, 29 Mediterranean lymphoma, 187 — therapy, 159 Liver-lung relationship, 189–191 Metal fume fever, 103 IgG antibodies, in Goodpasture disease, 151, — pulmonary complications of liver diseases, Methadone, toxicity, 87 152 190 Methotrexate, lung toxicity, 78 IIP see idiopathic interstitial pneumonias Loeffler, W., 69 MGUS, 187 ILD see interstitial lung disease Loeffler syndrome, 69 Microliths, 163 Inflammatory bowel disease (IBD), 194–197 Lofgren syndrome, 25 Microscopic polyangiitis (MPA), 143–145 — extrapulmonary manifestations, 194, 195 Lubliner, H., 3 — clinical features, 143, 144 — pulmonary manifestations, 194, 195, 196 Lung attenuation, decreased, 23 — diagnosis, 143, 144 Inhalation fever, 103–105 Lung biopsy, 15, 16 — incidence, 143 — causative agents, 104 — see also open lung biopsy; transbronchial — therapy, 143 Interlobular thickening, in lymphangitic lung biopsy; video-assisted thorascopic — Wegener granulomatosis vs, 143 carcinomatosis, 21 (VAT) lung biopsy Migratory pneumonitis, due to breast Interstitial lung disease (ILD) Lung cancer irradiation, 82–83 — classification, 10 — in idiopathic pulmonary fibrosis, 199, 200 Miyajima, M., 95 — definition, 7 — in pulmonary systemic sclerosis, 118, 200 Monoclonal gammopathy of uncertain — diagnosis, 7–17 — sarcoidosis and, 199 significance (MGUS), 187 —— bronchoalveolar lavage, 15–16 Lung cysts Morphine, 85 —— differential, 16–17 — in Langerhans cell histiocytosis, 22, 175, Mosaic pattern, 23 —— extrapulmonary features, 11 176, 178 MPA see microscopic polyangiitis —— histologic, 15 — in lymphangioleiomyomatosis, 22, 23 MPO-ANCA, 143, 144, 147, 148 —— history, 7 Lung function tests, 12, 14 MRI see magnetic resonance imaging —— laboratory and immunologic studies, — BOOP, 57 Muller, S. L., 69 12, 15 — IPF, 43 Multiple myeloma, 185–186 —— lung function tests, 12, 14 — IPH, 159 — incidence, 185 —— radiologic studies, 11–12 — LAM, 171 — lung parenchymal involvement, 186 —— signs, 11 — PAP, 167 — plasmacytoma, 185–186 —— symptoms,7,10 — PM/DM, 125 — pulmonary infections in, 186 —— see also HRCT — Wegener granulomatosis, 139 — thoracic cage involvement, 185 206 Index

Musculoskeletal sarcoidosis, 25, 31 PET see positron emission tomography — lung involvement frequency, 136 Myocardial sarcoidosis, 25, 29 PIE see pulmonary infiltration with — see also Wegener granulomatosis eosinophilia (PIE) syndromes Pulmonary infiltration with eosinophilia (PIE) N Pigeon breeder’s lung, 92 syndromes, 69 Necrotizing glomerulonephritis, in Pleura, in sarcoidosis, 34 Pulmonary Langerhans cell histiocytosis see microscopic polyangiitis, 143 Langerhans cell histiocytosis Necrotizing vasculitis, in Wegener — in liver disease, 190 Pulmonary ossification, causes, 164 granulomatosis, 139, 141 — in SLE, 123 Pulmonary plasmacytoma, 185–186 Nervous system, in sarcoidosis, 25, 30, 36 Pleural fluid cytoanalysis, rheumatoid Pulmonary sarcoidosis, 25, 35, 36 Neuroendocrine cells, 10 arthritis, 111 Pulmonary veno-occlusive disease (PVOD), Neurosarcoidosis, 30 PM see polymyositis 155, 157–158 Neutrophilic alveolitis Pneumoconioses, 97–101 — clinical features, 155, 157 — in AIP, 61 — benign, 101 — differential diagnosis, 158 — in IPF, 43, 44 — classification, 98 — primary vs, 158 — in metal fume fever, 103 — coal miner’s, 97, 99 — symptoms, 155 — rheumatoid arthritis-related, 107, 111 — hard-metal, 100 Pulmo-renal syndromes, differential diagnosis, Nodules, 23 Pneumocytes 144 — in Caplan syndrome, 21 — type I, 10 PVOD see pulmonary veno-occlusive disease — in sarcoidosis, 21 — type II, 10 Noncardiogenic (NCPE), Pneumonia, in multiple myeloma, 186 Q heroin-related, 85 Polyarthritis, in Sjögren syndrome, 129, 131 Quartz, effects, 97 Nonspecific interstitial pneumonia (NSIP), Polymer fume fever, 103 3–4, 37, 51–55 Polymyositis (PM), 125–127 R — cellular, 54 — incidence, 125 RA see rheumatoid arthritis — clinical conditions associated, 51, 52 — interstitial lung disease in, 125 Radiation-induced , 81 — clinical features, 51 — pulmonary manifestations, 125, 126 Radiation-induced lung diseases, 81–83 — diagnostic procedure, 51 — treatment, 125 — classification, 82 — fibrotic, 53, 54 Porto-pulmonary hypertension, 189 — pathogenesis, 82 — histological features, 54 Positron emission tomography (PET), 19 Radiation-induced pneumonitis, 81, 82 — lung lavage cell profiles, 16 — amyloidosis, 182 — histopathologic findings, 81, 82 — pathogenesis, 51 Posterior uveitis-chorioretinal punctiform Radiographs — prognosis, 51, 54 atrophy, 28 — AIP, 61, 62 — rheumatoid arthritis and, 107 Primary biliary cirrhosis (PBC), 191 — amyloidosis, 182, 184 — therapy, 55 — sarcoidosis vs, 191 — Behçet disease, 157 — UIP vs, 51, 52 Proptosis, 135, 137 — BOOP, 57, 58, 59 NSIP see nonspecific interstitial pneumonia Psychotropic drugs, interstitial drug-induced — CEP, 72 reactions, 75, 78 — cocaine abuse, 88 O Pulmonary acinus, 8 — CSS, 147, 149 Ocular sarcoidosis, 28, 36 Pulmonary alveolar microlithiasis (PAM), — DIP, 49 Open lung biopsy 163–164 — drug-induced lung diseases, 75, 76–77, 78 — AIP, 63 — diagnosis, 163 — features of ILD, 11–12 — in IIP diagnosis, 39 — incidence, 163 — Goodpasture disease, 151, 152 — IPF, 43 — therapy, 163 — heroin toxicity, 85, 86 — IPH, 159 Pulmonary alveolar proteinosis (PAP), 38, — hypersensitivity pneumonitis, 93, 94 — LAM, 171, 172 167–169 — IPF, 43 — Langerhans cell histiocytosis, 177 — acquired (idiopathic) form, 167 — IPH, 159, 160, 161 — LIP, 65, 66 — congenital form, 167 — LAM, 171, 172 — NSIP, 53 — diagnosis, 167 — Langerhans cell histiocytosis, 175, 176, — PAM, 163 — histopathological findings, 167, 169 177 — rheumatoid arthritis, 110 — prevalence, 167 — LIP, 65, 66 — Wegener granulomatosis, 139 — secondary form, 167 — lung cancer, 200 Opportunistic organisms, in PAP, 167 — treatment, 167 — lymphangitic carcinomatosis, 202 Oral ulcers, in Behçet disease, 155, 156 Pulmonary blood-gas barrier, 8 — methadone toxicity, 87 Organizing pneumonia see bronchiolitis Pulmonary calcification, causes, 164 — microscopic polyangiitis, 143, 145 obliterans organizing pneumonia Pulmonary capillaritis, in microscopic — NSIP, 51, 52, 53 Osler, William, 1, 3 polyangiitis, 143 — PAM, 163, 164 Pulmonary eosinophilia, 69 — PAP, 167, 168 P — drug-induced, 69, 71, 88 — PM/DM, 125, 126 PAM see pulmonary alveolar microlithiasis Pulmonary function tests see lung function — pneumoconioses, 98, 99, 100 Pancreatitis, 193, 194 tests — PVOD, 155, 157 Panda sign, 19, 20 Pulmonary hypertension — radiation-induced lung diseases, 81, 82 PAP see pulmonary alveolar proteinosis — pulmonary veno-occlusive disease vs, 158 — RB-ILD, 47, 48 Paraproteinemias, 181–187 — in SLE, 123 — rheumatoid arthritis, 108 Parenchymal shadows, classification, 11, 13 — in systemic sclerosis, 113 —— pulmonary involvement, 107, 109, 110 Parotid gland —— treatment agents, 117 — Sjögren syndrome, 129, 132 — enlargement, 11, 30 Pulmonary idiopathic vasculitides, 135 — SLE, 119, 121, 122 — in sarcoidosis, 30, 31 — ANCA positivity frequency, 136 — systemic sclerosis, 113, 116 PBC see primary biliary cirrhosis — anti-GMB antibody involvement, 135 — toxic inhalation injuries, 104, 105 Index 207

— Waldenstrom macrogammaglobulinemia, Scadding, G., 3 Testicular carcinoma, 201 186–187 Scleritis Tetramethylammonium hydroxide, effects, — Wegener granulomatosis, 136, 139, 140 — in IBD, 194, 195 105 Rales, 11 — with rheumatoid arthritis, 109 TGF-β, 171 Ramazzini da Capri, Bernardino, 1, 2 Scleroderma, 113 Thallium-201 chloride, 19 Raynaud phenomenon, with systemic sclerosis, — see also systemic sclerosis Thallium-201 imaging, 19 115 Secondary pulmonary lobule, 20 Thoracic myelomatosis, 185–186 RB-ILD see respiratory bronchiolitis associated Siderophages, 159, 162 Toxic fumes interstitial lung disease , 101 — acute exposure, 103 Renal cell carcinoma, 201 , 97 — chronic exposure, 103 Renal insufficiency, in Wegener — accelerated, 97, 98 Traction , 1 granulomatosis, 139 — complicated, 97 Transbronchial lung biopsy Respiratory bronchiolitis (RB), 47 — simple, 97, 98 — acute inhalation injury, 104 Respiratory bronchiolitis associated interstitial Silicotuberculosis, 97, 98 — drug-induced lung diseases, 75, 77 lung disease (RB-ILD), 37, 47–49 Silk Road disease see Behçet disease — in IIP diagnosis, 39 — clinical features, 47 Sjögren syndrome (SS), 129–132 — Langerhans cell histiocytosis, 177 — diagnostic procedure, 47 — ILD in, 129 — PAM, 163 — DIP vs, 49 — PBC and, 191 — rheumatoid arthritis, 110 — histopathological findings, 47, 48 — pleuropulmonary manifestations, 129, 131 Tropical eosinophilia, 69 — lung lavage cell profiles, 16 —— therapy, 132 Tuberculosis, sarcoidosis vs, 35 Rheumatoid arthritis (RA) Skin, in sarcoidosis, 25, 26–27 Tuberous sclerosis, lymphangioleiomyomatosis — joint manifestations, 107 SLE see systemic lupus erythematosus and, 171 — methotrexate-induced lung disease and, 78 Smoking — pulmonary involvement, 107–111 — conditions related, 47 U —— prevalence, 107 — diseases induced, 47 UIP see usual interstitial pneumonitis —— primary manifestations, 107, 108 — history, 7 Ulcerative colitis, 194, 195, 196 —— secondary manifestations, 107, 108 — in Langerhans cell histiocytosis, 175, 178 Usual interstitial pneumonitis (UIP), 3, 4 —— treatment, 107 Spleen, in sarcoidosis, 25, 29 — clinical conditions associated, 42 — with Sjögren syndrome, 129 SS see Sjögren syndrome — IPF and, 41, 43, 44 Rhonchi, 11 SSc see systemic sclerosis — NSIP vs, 51, 52 Rich, Arnold, 1, 3, 61 Stachybotrys atra, in IPH, 159 — rheumatoid arthritis and, 107, 110 Rokitansky, Carl von, 1 Stannosis, 101 Uveitis, 11 Romer, F., 199 Staphylococcus aureus, in Wegener — in Behçet disease, 155, 156 Rubin, E., 3 granulomatosis, 135 Systemic lupus erythematosus (SLE), 119–123 V S — anti-nuclear antibodies in, 119, 120, 121 Vasculitic skin rash, 144 Saddlenose deformity, 135 — butterfly rash, 120 Veno-occlusive lung disease see pulmonary Salivary glands, in sarcoidosis, 25, 30–31 — chronic forms of lung disease in, 119, 122 veno-occlusive disease Santayana, George, 1 — histopathology, 119, 122 Video-assisted thorascopic (VAT) lung biopsy, Sarcoid reaction, local, vs systemic sarcoidosis, — pleural effusion in, 123 15 201 — pleuropulmonary manifestations, 119, 121 — BOOP, 59 Sarcoidosis, 25–36 — treatment, 119, 123 — IPF, 43 — causes, 25 Systemic sclerosis (SSc), 113–118 Vitritis, 28 — chest , 25, 32, 33–34 — esophagus disease in, 113, 116, 193, 194 — clinical picture, 25, 26–31 — gastroesophageal reflux and, 193, 194 W — clinical presentations, 25, 26 — hands, 114 Waldenstrom macrogammaglobulinemia, — cutaneous, 26–27 — pathological features, 113, 117 186–187 — diagnosis, 25–35 — prognosis, 113 Walker, W., 107 — extrapulmonary features, 11 — progression, 114 Wegener granulomatosis (WG), 135–142 — histological evidence of noncaseating — pulmonary complications, 115 — cause, 135 granuloma, 32, 35 — pulmonary fibrosis in, 113, 117, 118 — clinical features, 135 — intrathoracic, stages, 32, 33 — pulmonary hypertension in, 113 — diagnosis, 139 — IPF vs, 14 —— treatment agents, 117 — histopathological findings, 139, 141 — lung cancer and, 199 — Raynaud phenomenon with, 115 — incidence, 135 — lung lavage cell profiles, 16 — treatment, 113, 118 — involvement of different organs, 136 — multisysytem, vs local sarcoid reaction, 201 — microscopic polyangiitis vs, 143 — myocardial, 25, 29 T — prognosis, 142 — ocular, 28, 36 Tachypnea, 11 — skin changes, 135, 139 — peribronchovascular thickening in, 22 Talc, effects in heroin abusers, 85, 87, 88, 100 — treatment, 139, 142 — prevalence rate, 25 Talcoasbestosis, 100 Wright, V., 107 — primary biliary cirrhosis vs, 191 Talcosilicosis, 97, 100 — pulmonary, 25, 35, 36 Talcosis, 97, 100 X — small nodules in, 21 TBUT test, 130 Xerophthalmia, 129, 130 — treatment, 36 Tear break-up time (TBUT) test, 130 Xerostomia, 129, 131 — tuberculosis vs, 35 Tear film dysfunction, 130 Xerotrachea, 129